https://www.healthcaretribunefrance.com/article/905614729-panntherapi-annonce-des-avanc-es-majeures-dans-son-d-veloppement-clinique-et-strat-gique Healthcare Tribune France en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/ https://www.healthcaretribunefrance.com/article/905614817-panntherapi-announces-significant-clinical-development-and-strategic-milestones Healthcare Tribune France en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi Announces Significant Clinical Development and Strategic Milestones https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/logo-png.png https://www.healthcaretribunefrance.com/article/904880672-abl-diagnostics-announces-two-new-scientific-publications-reinforcing-its-expertise-in-hiv-sequencing-based-genotyping Healthcare Tribune France en PressRelease 2026-04-13T12:10:56+00:00 ABL Diagnostics Announces Two New Scientific Publications, Reinforcing its Expertise in HIV Sequencing-based Genotyping https://www.healthcaretribunefrance.com/article/904984928-applications-open-for-dnda26-awards-celebrating-humanity-centered-design-for-societal-impact-and-global-well-being Healthcare Tribune France en PressRelease 2026-04-13T11:00:00+00:00 Applications Open for DNDA26 Awards: Celebrating Humanity-Centered Design for Societal Impact and Global Well-Being https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24830562-dnda25-laureates-3240x2160.jpeg https://www.healthcaretribunefrance.com/article/905424235-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous Healthcare Tribune France en PressRelease 2026-04-13T05:00:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/905424236-communiqu-de-presse-dupixent-de-sanofi-et-regeneron-approuv-dans-l-ue-comme-premier-m-dicament-cibl-contre-l-urticaire-chronique-spontan-e-chez Healthcare Tribune France en PressRelease 2026-04-13T05:00:00+00:00 Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg